Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03575832
Collaborator
National Cancer Institute (NCI) (NIH)
96
2
1
78.2
48
0.6

Study Details

Study Description

Brief Summary

This pilot trial studies how well Watchful Living works in improving quality of life in participants with prostate cancer that has not spread to other parts of the body who are on active surveillance and their partners. A social support lifestyle intervention (called Watchful Living) may help African American prostate cancer participants and their partners improve their quality of life, physical activity, diet, and inflammation.

Condition or Disease Intervention/Treatment Phase
  • Other: Counseling
  • Other: Informational Intervention
  • Other: Quality-of-Life Assessment
  • Other: Questionnaire Administration
  • Behavioral: Telephone-Based Intervention
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. To determine the feasibility of recruiting and implementing a lifestyle intervention for prostate cancer patients and their partners.
SECONDARY OBJECTIVES:
  1. To evaluate the preliminary efficacy of a lifestyle intervention in improving diet, physical activity, physical fitness, partner's support, quality of life, and inflammation at the end of the study (month 6).

  2. To conduct a process evaluation of the lifestyle intervention. III. Explore participants' satisfaction, likes/dislikes, strengths, weaknesses, and areas of improvement regarding the program.

OUTLINE:

Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
96 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Watchful Living: A Lifestyle Intervention for Black and Hispanic Prostate Cancer Patients and Their Partners
Actual Study Start Date :
Jan 25, 2018
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Jul 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Supportive care (exercise, nutrition counseling)

Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.

Other: Counseling
Complete nutrition counseling sessions
Other Names:
  • Counseling Intervention
  • Other: Informational Intervention
    Receive an exercise plan and printed materials

    Other: Quality-of-Life Assessment
    Ancillary studies
    Other Names:
  • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies

    Behavioral: Telephone-Based Intervention
    Receive telephone coaching calls

    Outcome Measures

    Primary Outcome Measures

    1. Recruitment and retention [Up to 8 months]

      Rates of study eligibility, recruitment, and retention will be assessed. Will maintain detailed information during the recruitment process regarding numbers of patients and their partners interested, eligible, ineligible (and reasons for ineligibility), and enrolled (and reasons for choosing not to enroll if deemed eligible). Will calculate rates of study eligibility, recruitment, and retention, along with 90% confidence intervals (CIs). Participant feedback will be summarized using means and standard deviations (SDs), along with graphical display (e.g., box plots). Will also assess reasons for withdrawal from study among those that chose to withdraw. Will examine the differences between dropout and non-dropout group at each time point by demographic factors such as age, gender, marital status, education, and income.

    2. Intervention adherence [Up to 8 months]

      The intervention adherence rate for each dyad is defined as the proportion of intervention sessions completed by both the patient and partner. Will also look at percentage of both patient and partner completing a minimum of 7 out of 10 coaching calls and both nutrition counseling sessions.

    Secondary Outcome Measures

    1. Surveillance lifestyle [Up to 8 months]

      Will report means, standard deviations, and distributions of survey measures (including pre-post changes of these measures, as appropriate) for ceiling/floor effects and restrictions in range. Outcome measures will be treated as continuous variables. Linear mixed models will be used when combined data from both patients and partners are analyzed due to their correlation within couples. Two-sided statistical tests will be performed, and the significance level for each test will be set at 0.05 without adjustment for multiple testing. All results from the statistical tests will be interpreted as hypothesis generating rather than conclusive findings. Will also perform paired t-tests to compare efficacy outcomes of interest between baseline and post intervention separately for patients and partners.

    2. Elements of the intervention that were successful and/or need improvements [Up to 8 months]

      Will conduct focus groups with a subsample of patient-partner dyads. Questions will address participants' experiences; thoughts about strengths, weaknesses, and needed improvements; perceptions about outcomes and impact; and overall reactions to and satisfaction with the intervention.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Self-identify as black or African American or Hispanic (patient)

    • Be greater than 18 years of age (patient and spouse or intimate partner)

    • Have 0-III stage prostate cancer (patient)

    • If treated, have completed therapy (e.g., surgery, chemo and/or radiation) (patient)

    • Enroll with a spouse or intimate partner (patient)

    • Do not meet physical activity recommendation (i.e., 150 minutes of moderate intensity physical activity per week) (patient and spouse or intimate partner)

    • Be ready and able to be physically active, as determined by a physician (letter from a physician or nurse practitioner) (patient and spouse or intimate partner)

    • Not participate in another physical activity, diet, or lifestyle program (patient)

    • Have a valid home address and telephone number (patient)

    • Internet access at home or other location (e.g., work, church, library, community center, etc.) (spouse or intimate partner)

    • Patients on active surveillance will be included

    Exclusion Criteria:
    • They have an active noncutaneous malignancy at any site (patient)

    • Had prior radiation therapy for treatment of the primary tumor (patient)

    • Have planned concomitant immunotherapy, hormonal therapy, chemotherapy, or radiation therapy during the study period (patient)

    • Are enrolled in another active surveillance protocol (patient)

    • Participated in formative focus groups for this study (patient and spouse or intimate partner)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Harris Health System (LBJ) Houston Texas United States 77026
    2 M D Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • M.D. Anderson Cancer Center
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Lorna McNeill, M.D. Anderson Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    M.D. Anderson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT03575832
    Other Study ID Numbers:
    • 2017-0556
    • NCI-2018-01406
    • 2017-0556
    First Posted:
    Jul 3, 2018
    Last Update Posted:
    Mar 7, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 7, 2022